Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-valent pneumococcal conjugate vaccine + AS02V
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 11-valent pneumococcal conjugate vaccine + AS02V is an investigational vaccine candidate developed by GSK Biologicals for the prevention of pneumococcal disease caused by Streptococcus pneumoniae. The vaccine consists of capsular polysaccharides from 11 distinct pneumococcal serotypes, which are conjugated to a carrier protein (Protein D, derived from non-typeable Haemophilus influenzae, for at least a subset of the serotypes). It is formulated with GSK's proprietary AS02V adjuvant system, an oil-in-water emulsion containing the immunostimulants MPL (3-O-desacyl-4'-monophosphoryl lipid A) and QS-21. This adjuvant system is designed to enhance the immunogenicity of the vaccine, particularly the induction of robust antibody and cellular immune responses. The candidate was evaluated in Phase I/II clinical trials in healthy adults but did not progress to regulatory approval in this specific 11-valent adjuvanted form.
- Other names
- 11-valent pneumococcal conjugate vaccine adjuvanted with AS02VGSK 11-valent pneumococcal conjugate vaccineGSK11-valent pneumococcal conjugate vaccineGSK-11-valent pneumococcal conjugate vaccine11-valent pneumococcal polysaccharide-protein D conjugate vaccine + AS02V
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)PD (Protein D)CholesterolTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on 11-valent pneumococcal conjugate vaccine + AS02V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11-valent pneumococcal conjugate vaccine + AS02V.